FDA to Review Afrezza: First Needle-Free Insulin for Children https://ymaho.com/fda-to-review-afrezza-first-needle-free-insulin-for-children
On May 29, 2026, the FDA will decide on Afrezza inhaled insulin for children aged 4–17. Learn why this is a market shift and a chance for a needle-free life. Read the analysis.
FDA to Review Inhaled Insulin Afrezza for Children https://ymaho.com/fda-to-review-inhaled-insulin-afrezza-for-children
On May 29, FDA will decide on needle-free insulin Afrezza for children aged 4–17. Learn why this is a paradigm shift in diabetology. Detailed analysis in the article.
AI eye scanner: early diagnosis of Parkinson's and dementia https://ymaho.com/ai-eye-scanner-early-diagnosis-of-parkinson-s-and-dementia
CCM technology with AI detects dementia and Parkinson's disease in minutes through a corneal image. Learn how needle-free scanning will change neurology.
Peptide boom: myostimulator creams replace Botox https://ymaho.com/peptide-boom-myostimulator-creams-replace-botox
Creams with peptides mimic the effect of botulinum toxin without injections. Learn about the neurocosmetics boom of 2026: peptide complexes for smoothing wrinkles and home facial rejuvenation.